個別化がんワクチンの世界市場レポート 2025年

個別化がんワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年には、CAGR6.7％で3,360億3,000万米ドルに成長します。予測期間の成長は、精密医療の進歩、がん研究への資金提供の増加、がん患者の有病率の上昇、遺伝子配列決定技術の向上、個別化治療オプションへの関心の高まりに起因すると考えられます。予測期間における主要動向には、ワクチン設計における人工知能の統合、多抗原と新抗原ベースのワクチンの進歩、腫瘍モニタリングのためのリキッドバイオプシーの使用の増加、併用療法の拡大、個別化治療レジメンの重視などがあります。

がん罹患率の上昇は、今後数年間における個別化がんワクチン市場の成長を促進すると予測されています。がんには、身体の他の部位に転移する可能性のある異常な細胞増殖を特徴とするさまざまな疾患が含まれます。このようながん有病率の増加は、人口の高齢化、ライフスタイルの変化、環境汚染物質への曝露、遺伝的素因、診断方法の進歩などの要因に起因しています。個別化がんワクチンは、患者それぞれに固有の腫瘍抗原を特異的に標的とすることで、がん細胞を識別し排除する免疫系の能力を高め、この有病率の上昇と闘うことを目指しています。例えば、2024年7月にオーストラリア保健福祉ラボが発表した報告書によると、オーストラリアにおけるがんの診断件数は、2022年の16万570件から2023年には16万4,694件に増加し、大幅な増加を示しています。このように、がんの有病率の増加が個別化がんワクチン市場の拡大を後押ししています。

個別化がんワクチン市場の主要参入企業は、特定のがん変異に対処する精度を向上させるために、個別化免疫療法などの革新的な治療法の開発に注力しています。こうした個別化免疫療法は、患者固有の遺伝子や腫瘍のプロファイルを活用し、がんに対する免疫反応を高めるオーダーメイドの治療法です。例えば、2024年8月、米国の医療機関であるUCLAヘルスは、がんワクチンの安全性と有効性を評価する画期的な臨床検査を開始しました。UCLAで開発されたこのワクチンは、びまん性半球神経膠腫（思春期や若年成人によく見られる非常に侵攻性の高い脳腫瘍）に関連するH3 G34変異を標的とする個別化免疫療法アプローチを採用しています。この方法は、樹状細胞を利用して、この突然変異によって引き起こされるRNAの破壊に対して特異的に免疫系を活性化させるものです。他のがんの治療でも可能性が示されているこの戦略は、治療の選択肢が限られ、生存率が低いことが多い患者の予後を改善することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の個別化がんワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の個別化がんワクチン市場：成長率分析
• 世界の個別化がんワクチン市場の実績：規模と成長、2019～2024年
• 世界の個別化がんワクチン市場の予測：規模と成長、2024～2029年、2034年
• 世界の個別化がんワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の個別化がんワクチン市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 予防用がんワクチン
• 治療用がんワクチン
• 世界の個別化がんワクチン市場：がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺がん
• 乳がん
• 大腸がん
• 白血病
• 前立腺がん
• 子宮頸がん
• 神経膠芽腫
• 世界の個別化がんワクチン市場：作用機序別、実績と予測、2019～2024年、2024～2029年、2034年
• 腫瘍関連抗原（TAA）
• 腫瘍特異抗原（TSA）
• がん薬理ゲノミクスにおける体細胞変異
• ゲノム多型性に向けた薬理ゲノム学
• その他の作用機序
• 世界の個別化がんワクチン市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射剤
• その他
• 世界の個別化がんワクチン市場：最終用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他
• 世界の個別化がんワクチン市場、がん予防ワクチンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• HPVワクチン
• B型肝炎ワクチン
• 混合ワクチン
• 世界の個別化がんワクチン市場、治療用がんワクチンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 樹状細胞ワクチン
• ペプチドベースのワクチン
• DNAワクチン
• RNAワクチン
• 全細胞ワクチン

第7章 地域別・国別分析

• 世界の個別化がんワクチン市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の個別化がんワクチン市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 個別化がんワクチン市場：競合情勢
• 個別化がんワクチン市場：企業プロファイル
  • Merck & Co Inc
  • GlaxoSmithKline Plc
  • NEC Corporation
  • Moderna Inc
  • Catalent Inc

第31章 その他の大手企業と革新的企業

• UCLA Health
• Genetech Inc
• NHS England
• CureVac AG
• Personalis Inc
• Achilles Therapeutics Plc
• Healio
• Moffitt Corporation
• BioPharma APAC
• Celebrity Angels
• EpiVax Therapeutics Inc.
• Evaxion BIoTech AS
• Geneos Therapeutics Inc
• IFL Science
• ISA Pharmaceuticals BV

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 個別化がんワクチン市場、2029年：新たな機会を提供する国
• 個別化がんワクチン市場、2029年：新たな機会を提供するセグメント
• 個別化がんワクチン市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Personalized cancer vaccines are treatments specifically designed to match an individual's unique tumor profile, with the goal of stimulating the immune system to target and eliminate cancer cells. These vaccines enhance the body's ability to recognize and combat specific cancer types, potentially improving treatment effectiveness and reducing the likelihood of recurrence.

The main categories of personalized cancer vaccines include preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines aim to protect against infections or conditions that could lead to cancer. These vaccines can be utilized for various cancer types, including lung cancer, breast cancer, colorectal cancer, leukemia, prostate cancer, cervical cancer, and glioblastoma. They operate through different mechanisms of action, such as targeting tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), and addressing somatic mutations in cancer pharmacogenomics, among other factors. They are administered via various routes, including injectables, and are used in a range of settings, such as hospitals and clinics.

The personalized cancer vaccines market research report is one of a series of new reports from The Business Research Company that provides personalized cancer vaccines market statistics, including personalized cancer vaccines industry global market size, regional shares, competitors with a personalized cancer vaccines market share, detailed personalized cancer vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cancer vaccines industry. This personalized cancer vaccines market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The personalized cancer vaccines market size has grown strongly in recent years. It will grow from $242.29 billion in 2024 to $259.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to advancements in genomic research, development of targeted therapies, increased understanding of tumor immunology, progress in vaccine technology and growing clinical trial data supporting efficacy.

The personalized cancer vaccines market size is expected to see strong growth in the next few years. It will grow to $336.03 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advancements in precision medicine, increasing funding for cancer research, rising prevalence of cancer cases, improvements in genetic sequencing technologies and growing interest in personalized treatment options. Major trends in the forecast period include the integration of artificial intelligence in vaccine design, advances in multi-antigen and neoantigen-based vaccines, increased use of liquid biopsies for tumor monitoring, expansion of combination therapies, and greater focus on personalized treatment regimens.

The rising incidence of cancer is projected to drive the growth of the personalized cancer vaccine market in the coming years. Cancer encompasses a range of diseases characterized by abnormal cell growth that can metastasize to other areas of the body. This increase in cancer prevalence is attributed to factors such as aging populations, changes in lifestyle, exposure to environmental pollutants, genetic predispositions, and advancements in diagnostic methods. Personalized cancer vaccines aim to combat this rising prevalence by specifically targeting tumor antigens that are unique to each patient, thereby enhancing the immune system's ability to identify and eliminate cancer cells. For example, a report from the Australian Institute of Health and Welfare in July 2024 indicated that cancer diagnoses in Australia rose from 160,570 cases in 2022 to 164,694 in 2023, showcasing a significant increase. Thus, the growing prevalence of cancer is propelling the expansion of the personalized cancer vaccine market.

Key players in the personalized cancer vaccine market are concentrating on developing innovative therapeutic options, such as personalized immunotherapy, to improve precision in addressing specific cancer mutations. These personalized immunotherapy solutions are tailored treatments that leverage a patient's unique genetic and tumor profiles to enhance immune responses against cancer. For instance, in August 2024, UCLA Health, a healthcare organization based in the U.S., initiated a groundbreaking clinical trial to assess the safety and efficacy of a cancer vaccine. This vaccine, developed at UCLA, employs a personalized immunotherapy approach to target the H3 G34 mutation associated with diffuse hemispheric gliomas, a highly aggressive brain tumor commonly found in adolescents and young adults. The method utilizes dendritic cells to activate the immune system specifically against the RNA disruptions caused by this mutation. This strategy, which has shown potential in treating other cancers, aims to improve outcomes for patients who often have limited treatment options and short survival rates.

In March 2022, NEC OncoImmunity AS, a biotechnology firm from Norway, acquired the neoantigen program assets from VAXIMM GmbH for an undisclosed sum. This acquisition is intended to bolster NEC OncoImmunity's development of neoantigen cancer vaccines, including patents and existing collaboration agreements. This strategic move will enhance NEC OncoImmunity's capacity to advance personalized cancer immunotherapies, building on their prior collaboration with VAXIMM. VAXIMM GmbH is a biopharmaceutical company based in Germany that specializes in the development of personalized cancer vaccines.

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc, GlaxoSmithKline Plc, NEC Corporation, Moderna Inc, Catalent Inc, UCLA Health, Genetech Inc, NHS England, CureVac AG, Personalis Inc, Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc, IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh

North America was the largest region in the personalized cancer vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the personalized cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The personalized cancer vaccines market consists of sales of patient-specific vaccines, neoantigen-based therapies, dendritic cell-based vaccines and peptide-based immunotherapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Personalized Cancer Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on personalized cancer vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for personalized cancer vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The personalized cancer vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Cervical Cancer; Glioblastoma
• 3) By Mechanism Of Action: Tumor Associated Antigens (TAAs); Tumor Specific Antigens (TSAs); Somatic Mutations In Cancer Pharmacogenomics; Pharmacogenomics Towards Genomic Polymorphism; Other Mechanisms Of Action
• 4) By Route Of Administration: Injectables; Other Routes Of Administration
• 5) By End Use: Hospitals; Clinic; Other End Users
• Subsegments:
• 1) By Preventive Cancer Vaccines: HPV Vaccines; Hepatitis B Vaccines; Combination Vaccines
• 2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines; Peptide-Based Vaccines; DNA Vaccines; RNA Vaccines; Whole Cell Vaccines
• Companies Mentioned: Merck & Co Inc; GlaxoSmithKline Plc; NEC Corporation; Moderna Inc; Catalent Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Personalized Cancer Vaccines Market Characteristics

3. Personalized Cancer Vaccines Market Trends And Strategies

4. Personalized Cancer Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Personalized Cancer Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Personalized Cancer Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Personalized Cancer Vaccines Market Growth Rate Analysis
• 5.4. Global Personalized Cancer Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Personalized Cancer Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Personalized Cancer Vaccines Total Addressable Market (TAM)

6. Personalized Cancer Vaccines Market Segmentation

• 6.1. Global Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• 6.2. Global Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Prostate Cancer
• Cervical Cancer
• Glioblastoma
• 6.3. Global Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Associated Antigens (TAAs)
• Tumor Specific Antigens (TSAs)
• Somatic Mutations In Cancer Pharmacogenomics
• Pharmacogenomics Towards Genomic Polymorphism
• Other Mechanisms Of Action
• 6.4. Global Personalized Cancer Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Other Routes Of Administration
• 6.5. Global Personalized Cancer Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinic
• Other End Users
• 6.6. Global Personalized Cancer Vaccines Market, Sub-Segmentation Of Preventive Cancer Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HPV Vaccines
• Hepatitis B Vaccines
• Combination Vaccines
• 6.7. Global Personalized Cancer Vaccines Market, Sub-Segmentation Of Therapeutic Cancer Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dendritic Cell Vaccines
• Peptide-Based Vaccines
• DNA Vaccines
• RNA Vaccines
• Whole Cell Vaccines

7. Personalized Cancer Vaccines Market Regional And Country Analysis

• 7.1. Global Personalized Cancer Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Personalized Cancer Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Personalized Cancer Vaccines Market

• 8.1. Asia-Pacific Personalized Cancer Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Personalized Cancer Vaccines Market

• 9.1. China Personalized Cancer Vaccines Market Overview
• 9.2. China Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Personalized Cancer Vaccines Market

• 10.1. India Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Personalized Cancer Vaccines Market

• 11.1. Japan Personalized Cancer Vaccines Market Overview
• 11.2. Japan Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Personalized Cancer Vaccines Market

• 12.1. Australia Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Personalized Cancer Vaccines Market

• 13.1. Indonesia Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Personalized Cancer Vaccines Market

• 14.1. South Korea Personalized Cancer Vaccines Market Overview
• 14.2. South Korea Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Personalized Cancer Vaccines Market

• 15.1. Western Europe Personalized Cancer Vaccines Market Overview
• 15.2. Western Europe Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Personalized Cancer Vaccines Market

• 16.1. UK Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Personalized Cancer Vaccines Market

• 17.1. Germany Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Personalized Cancer Vaccines Market

• 18.1. France Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Personalized Cancer Vaccines Market

• 19.1. Italy Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Personalized Cancer Vaccines Market

• 20.1. Spain Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Personalized Cancer Vaccines Market

• 21.1. Eastern Europe Personalized Cancer Vaccines Market Overview
• 21.2. Eastern Europe Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Personalized Cancer Vaccines Market

• 22.1. Russia Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Personalized Cancer Vaccines Market

• 23.1. North America Personalized Cancer Vaccines Market Overview
• 23.2. North America Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Personalized Cancer Vaccines Market

• 24.1. USA Personalized Cancer Vaccines Market Overview
• 24.2. USA Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Personalized Cancer Vaccines Market

• 25.1. Canada Personalized Cancer Vaccines Market Overview
• 25.2. Canada Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Personalized Cancer Vaccines Market

• 26.1. South America Personalized Cancer Vaccines Market Overview
• 26.2. South America Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Personalized Cancer Vaccines Market

• 27.1. Brazil Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Personalized Cancer Vaccines Market

• 28.1. Middle East Personalized Cancer Vaccines Market Overview
• 28.2. Middle East Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Personalized Cancer Vaccines Market

• 29.1. Africa Personalized Cancer Vaccines Market Overview
• 29.2. Africa Personalized Cancer Vaccines Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Personalized Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Personalized Cancer Vaccines Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Personalized Cancer Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Personalized Cancer Vaccines Market Competitive Landscape
• 30.2. Personalized Cancer Vaccines Market Company Profiles
  • 30.2.1. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. NEC Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Moderna Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Catalent Inc Overview, Products and Services, Strategy and Financial Analysis

31. Personalized Cancer Vaccines Market Other Major And Innovative Companies

• 31.1. UCLA Health
• 31.2. Genetech Inc
• 31.3. NHS England
• 31.4. CureVac AG
• 31.5. Personalis Inc
• 31.6. Achilles Therapeutics Plc
• 31.7. Healio
• 31.8. Moffitt Corporation
• 31.9. BioPharma APAC
• 31.10. Celebrity Angels
• 31.11. EpiVax Therapeutics Inc.
• 31.12. Evaxion Biotech AS
• 31.13. Geneos Therapeutics Inc
• 31.14. IFL Science
• 31.15. ISA Pharmaceuticals BV

32. Global Personalized Cancer Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Personalized Cancer Vaccines Market

34. Recent Developments In The Personalized Cancer Vaccines Market

35. Personalized Cancer Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Personalized Cancer Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Personalized Cancer Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Personalized Cancer Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer